Patient characteristics and costs of severe sepsis and septic shock in Quebec

被引:27
作者
Letarte, J
Longo, CJ
Pelletier, J
Nabonne, B
Fisher, HN
机构
[1] Eli Lilly Canada Inc, Scarborough, ON M1N 2E8, Canada
[2] Nextractor Inc, Montreal, PQ, Canada
关键词
D O I
10.1053/jcrc.2002.33028
中图分类号
R4 [临床医学];
学科分类号
1002 ; 100602 ;
摘要
Background: We investigated the cost of health care resources for the treatment of severe sepsis and/or septic shock patients. Materials and Methods: One hundred retrospective chart abstractions from patients with severe sepsis or septic shock were included. The average cost, per episode, through day 28, as well as an analysis of a patient subset through 1 year was calculated. Mean values for all abstracted patient's costs and outcomes, as well as analyses of the survivor and nonsurvivor populations, were undertaken. Data from the Canadian Institute for Health Information and recent published literature were used to estimate the number of severe sepsis cases, and the resulting burden of illness for Quebec. Results: The mean cost for all patients abstracted was $11,474 per episode of care ($1,064/day). The survivors had a mean cost for their treatment of $16,228 per episode of care ($877/day). The total cost per episode was $7,584 per nonsurvivor ($1,724/day). An average cost of $27,481 for survivors after day 28 through 1 year was calculated. The burden of severe sepsis was estimated to be $36.4 to $72.9 million per year, but higher if costs beyond day 28 are included. Conclusions: The cost of severe sepsis is a significant burden to the Quebec health care system. Copyright 2002, Elsevier Science (USA). All rights reserved.
引用
收藏
页码:39 / 49
页数:11
相关论文
共 15 条
[1]   Epidemiology of severe sepsis in the United States: Analysis of incidence, outcome, and associated costs of care [J].
Angus, DC ;
Linde-Zwirble, WT ;
Lidicker, J ;
Clermont, G ;
Carcillo, J ;
Pinsky, MR .
CRITICAL CARE MEDICINE, 2001, 29 (07) :1303-1310
[2]   Efficacy and safety of recombinant human activated protein C for severe sepsis. [J].
Bernard, GR ;
Vincent, JL ;
Laterre, P ;
LaRosa, SP ;
Dhainaut, JF ;
Lopez-Rodriguez, A ;
Steingrub, JS ;
Garber, GE ;
Helterbrand, JD ;
Ely, EW ;
Fisher, CJ .
NEW ENGLAND JOURNAL OF MEDICINE, 2001, 344 (10) :699-709
[3]   INCIDENCE, RISK-FACTORS, AND OUTCOME OF SEVERE SEPSIS AND SEPTIC SHOCK IN ADULTS - A MULTICENTER PROSPECTIVE-STUDY IN INTENSIVE-CARE UNITS [J].
BRUNBUISSON, C ;
DOYON, F ;
CARLET, J ;
DELLAMONICA, P ;
GOUIN, F ;
LEPOUTRE, A ;
MERCIER, JC ;
OFFENSTADT, G ;
REGNIER, B .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1995, 274 (12) :968-974
[4]  
*CAN I HLTH INF, 1997, GUID MAN INF SYST CA
[5]  
*CCOHTA, 1996, GUID DOC COST PROC
[6]  
CDC, 1990, JAMA-J AM MED ASSOC, V263, P937
[7]   The patient-related costs of care for sepsis patients in a United Kingdom adult general intensive care unit [J].
Edbrooke, DL ;
Hibbert, CL ;
Kingsley, JM ;
Smith, S ;
Bright, NM ;
Quinn, JM .
CRITICAL CARE MEDICINE, 1999, 27 (09) :1760-1767
[8]   A SIMPLE MULTIPLE SYSTEM ORGAN FAILURE SCORING SYSTEM PREDICTS MORTALITY OF PATIENTS WHO HAVE SEPSIS SYNDROME [J].
HEBERT, PC ;
DRUMMOND, AJ ;
SINGER, J ;
BERNARD, GR ;
RUSSELL, JA .
CHEST, 1993, 104 (01) :230-235
[9]   Use of predicted risk of mortality to evaluate the efficacy of anticytokine therapy in sepsis [J].
Knaus, WA ;
Harrell, FE ;
LaBrecque, JF ;
Wagner, DP ;
Pribble, JP ;
Draper, EA ;
Fisher, CJ ;
Soll, L ;
Astiz, M ;
Rackow, EC ;
Carpati, C ;
Balk, RA ;
Friedman, B ;
Mure, AJ ;
Shapiro, E ;
Melhom, L ;
Shapiro, MJ ;
Taylor, R ;
Keegan, M ;
OBrien, J ;
Greenman, RL ;
Schein, R ;
Pena, M ;
Wasserlouf, M ;
Iberti, TJ ;
Oropello, J ;
Benjamin, E ;
DelGuidice, R ;
Emmanuel, G ;
Lie, T ;
Anderson, L ;
Marshall, J ;
DeMajo, W ;
Rotstein, O ;
Foster, D ;
Abraham, E ;
Middleton, H ;
Perry, C ;
Levy, H ;
Fry, DE ;
Simpson, SQ ;
Crowell, RE ;
Neidhart, M ;
Stevens, D ;
Coffman, T ;
Narasimhan, N ;
Merrick, DK ;
Berquist, W ;
Matzel, K ;
Huebler, M .
CRITICAL CARE MEDICINE, 1996, 24 (01) :46-56
[10]  
LINDEZWIRBLE WT, 2001, VALUE HEALTH, V4, P60